Today, after months of effort by APhA and other stakeholders, FDA has updated the EUA for the COVID-19 oral antiviral, Paxlovid, to permit pharmacists to order and prescribe Paxlovid under certain conditions.

The Board of Trustees of the American Pharmacists Association announced today that Ilisa Bernstein, PharmD, JD, FAPhA, has been named Interim CEO, effective immediately. Bernstein’s appointment follows the departure of Scott Knoer, PharmD, MS, as Executive Vice-President and CEO.

WASHINGTON, DC—The American Pharmacists Association (APhA) is deeply saddened by the horrific mass shooting in Uvalde, Texas, elementary school in which a gunman took the lives of at least 19 young children and two dedicated teachers.

WASHINGTON, D.C.—CMS has issued a final rule eliminating Part D plans’ and PBMs’ use of retroactive direct and indirect remuneration (DIR) fees beginning on January 1, 2024 (contract year 2024). The American Pharmacists Association (APhA) and many of its members submitted comments to CMS on the proposal. APhA appreciates CMS’ efforts to end the uncertainty and lack of drug cost transparency at the pharmacy caused by retroactive DIR fees.

WASHINGTON, DC – The American Pharmacists Association released the following statement in response to an April 12, 2022, letter from the American Medical Association (AMA) to Representatives Kind and McKinley regarding H.R. 7213, the “Equitable Community Access to Pharmacist Services Act.”